antipyrine has been researched along with ALS - Amyotrophic Lateral Sclerosis in 38 studies
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Edaravone slowed the rate of functional decline in subjects with amyotrophic lateral sclerosis (ALS) in phase 3 study MCI186-19 (Study 19)." | 9.51 | Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]. ( Apple, S; Brooks, BR; Heiman-Patterson, T; Liu, S; Wiedau-Pazos, M; Zhang, J, 2022) |
| "In a previous phase 3 study in patients with amyotrophic lateral sclerosis (ALS), edaravone did not show a significant difference in the Revised ALS Functional Rating Scale (ALSFRS-R) score compared with placebo." | 9.24 | Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. ( , 2017) |
| "Our objective was to explore the efficacy and safety of edaravone in amyotrophic lateral sclerosis (ALS) patients with a Japan ALS severity classification of Grade 3." | 9.24 | Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation). ( , 2017) |
| "Our first phase III study failed to demonstrate efficacy of edaravone for amyotrophic lateral sclerosis (ALS) compared to placebo." | 9.24 | A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. ( , 2017) |
| "Following the first phase III study of edaravone for amyotrophic lateral sclerosis (ALS), this extension study was performed to evaluate longer-term efficacy and safety." | 9.24 | Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. ( , 2017) |
| "Compared to age-matched healthy controls (n = 55), patients with amyotrophic lateral sclerosis (ALS) (n = 26) showed increased oxidative stress as indicated by a significantly increased percentage of oxidized coenzyme Q10 (%CoQ10) in total plasma coenzyme Q10, a significantly decreased level of plasma uric acid, and a significantly decreased percentage of polyunsaturated fatty acids in total plasma free fatty acids (FFA)." | 9.22 | Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. ( Miyazaki, Y; Nagase, M; Yamamoto, Y; Yoshino, H, 2016) |
| "Our objective was to confirm the efficacy and safety of edaravone in amyotrophic lateral sclerosis (ALS) patients." | 9.19 | Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. ( Abe, K; Akimoto, M; Aoki, M; Doyu, M; Hamada, C; Itoyama, Y; Kondo, K; Sobue, G; Tsuji, S; Yoneoka, T; Yoshino, H, 2014) |
| "The free radical scavenger edaravone is a proven neuroprotective drug for patients with amyotrophic lateral sclerosis (ALS)." | 7.96 | Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients. ( Abe, K; Hishikawa, N; Ikegami, K; Kawahara, Y; Matsumoto, N; Nakano, Y; Nomura, E; Ohta, Y; Omote, Y; Osakada, Y; Sasaki, R; Sato, K; Tadokoro, K; Takahashi, Y; Takamiya, M; Takemoto, M; Tsunoda, K; Yamashita, T; Yunoki, T, 2020) |
| "Edaravone was descriptively favoured for each ALSFRS-R item and each of the four ALSFRS-R domains at the end of cycle 6 (ALL LOCF), suggesting a generalised effect of edaravone in slowing functional decline across all anatomical regions." | 6.84 | Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis. ( Liu, S; Palumbo, J; Takahashi, F; Takei, K; Tsuda, K, 2017) |
| " Endpoints included treatment-emergent adverse events (TEAEs), including AEs leading to discontinuation, serious adverse events (SAEs), and deaths." | 6.84 | A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies. ( Ishizaki, K; Kalin, A; Kim, A; Medina-Paraiso, E; Saita, T; Wasaki, M; Zhang, Y, 2017) |
| "Edaravone is a strong antioxidant that prevents oxidative stress from inducing motor neuron death in ALS patients." | 6.58 | Edaravone: a new hope for deadly amyotrophic lateral sclerosis. ( Bhandari, R; Kuhad, A, 2018) |
| "Edaravone, is a free-radical scavenger, it has been shown to inhibit motor neuron death in animal models by reducing oxidative stress & it has shown efficacy in a small subset of people with ALS." | 5.72 | Efficacy and Safety of Edaravone in Amyotrophic Lateral Sclerosis Patients in Indian Population. ( Gupta, S; Singal, A; Soni, R; Tomar, S, 2022) |
| "Edaravone slowed the rate of functional decline in subjects with amyotrophic lateral sclerosis (ALS) in phase 3 study MCI186-19 (Study 19)." | 5.51 | Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]. ( Apple, S; Brooks, BR; Heiman-Patterson, T; Liu, S; Wiedau-Pazos, M; Zhang, J, 2022) |
| "In a previous phase 3 study in patients with amyotrophic lateral sclerosis (ALS), edaravone did not show a significant difference in the Revised ALS Functional Rating Scale (ALSFRS-R) score compared with placebo." | 5.24 | Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. ( , 2017) |
| "Our objective was to explore the efficacy and safety of edaravone in amyotrophic lateral sclerosis (ALS) patients with a Japan ALS severity classification of Grade 3." | 5.24 | Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation). ( , 2017) |
| "Our first phase III study failed to demonstrate efficacy of edaravone for amyotrophic lateral sclerosis (ALS) compared to placebo." | 5.24 | A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. ( , 2017) |
| "Following the first phase III study of edaravone for amyotrophic lateral sclerosis (ALS), this extension study was performed to evaluate longer-term efficacy and safety." | 5.24 | Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. ( , 2017) |
| "Compared to age-matched healthy controls (n = 55), patients with amyotrophic lateral sclerosis (ALS) (n = 26) showed increased oxidative stress as indicated by a significantly increased percentage of oxidized coenzyme Q10 (%CoQ10) in total plasma coenzyme Q10, a significantly decreased level of plasma uric acid, and a significantly decreased percentage of polyunsaturated fatty acids in total plasma free fatty acids (FFA)." | 5.22 | Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. ( Miyazaki, Y; Nagase, M; Yamamoto, Y; Yoshino, H, 2016) |
| "Our objective was to confirm the efficacy and safety of edaravone in amyotrophic lateral sclerosis (ALS) patients." | 5.19 | Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. ( Abe, K; Akimoto, M; Aoki, M; Doyu, M; Hamada, C; Itoyama, Y; Kondo, K; Sobue, G; Tsuji, S; Yoneoka, T; Yoshino, H, 2014) |
| "The free radical scavenger edaravone is a proven neuroprotective drug for patients with amyotrophic lateral sclerosis (ALS)." | 3.96 | Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients. ( Abe, K; Hishikawa, N; Ikegami, K; Kawahara, Y; Matsumoto, N; Nakano, Y; Nomura, E; Ohta, Y; Omote, Y; Osakada, Y; Sasaki, R; Sato, K; Tadokoro, K; Takahashi, Y; Takamiya, M; Takemoto, M; Tsunoda, K; Yamashita, T; Yunoki, T, 2020) |
| "We evaluated a battery of functional tests for investigating the effects of edaravone, a free radical scavenger, in SOD1 transgenic (H46R) rat model of amyotrophic lateral sclerosis." | 3.77 | Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger. ( Aoki, M; Itoyama, Y; Mizuno, H; Suzuki, N; Warita, H; Yuki, S, 2011) |
| "Edaravone was descriptively favoured for each ALSFRS-R item and each of the four ALSFRS-R domains at the end of cycle 6 (ALL LOCF), suggesting a generalised effect of edaravone in slowing functional decline across all anatomical regions." | 2.84 | Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis. ( Liu, S; Palumbo, J; Takahashi, F; Takei, K; Tsuda, K, 2017) |
| " Endpoints included treatment-emergent adverse events (TEAEs), including AEs leading to discontinuation, serious adverse events (SAEs), and deaths." | 2.84 | A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies. ( Ishizaki, K; Kalin, A; Kim, A; Medina-Paraiso, E; Saita, T; Wasaki, M; Zhang, Y, 2017) |
| "Edaravone is a strong antioxidant that prevents oxidative stress from inducing motor neuron death in ALS patients." | 2.58 | Edaravone: a new hope for deadly amyotrophic lateral sclerosis. ( Bhandari, R; Kuhad, A, 2018) |
| " Questions regarding whether the dosing regimen could be simplified or improved, the duration of the effects, and the timing of the potential treatment to different stages of disease remain to be answered." | 2.55 | What can we learn from the edaravone development program for ALS? ( Maragakis, NJ, 2017) |
| "Edaravone has recently been approved as a new therapeutic option for ALS in Japan." | 2.53 | Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis. ( Kiernan, MC; Noto, Y; Shibuya, K; Vucic, S, 2016) |
| "Edaravone, is a free-radical scavenger, it has been shown to inhibit motor neuron death in animal models by reducing oxidative stress & it has shown efficacy in a small subset of people with ALS." | 1.72 | Efficacy and Safety of Edaravone in Amyotrophic Lateral Sclerosis Patients in Indian Population. ( Gupta, S; Singal, A; Soni, R; Tomar, S, 2022) |
| "Edaravone is a free-radical scavenger, an agent being widely used for cerebral ischemia in Japan." | 1.35 | Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. ( Ito, H; Kaneko, S; Kusaka, H; Nakano, S; Ohnishi, S; Wate, R; Zhang, J, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (10.53) | 29.6817 |
| 2010's | 29 (76.32) | 24.3611 |
| 2020's | 5 (13.16) | 2.80 |
| Authors | Studies |
|---|---|
| Tomar, S | 1 |
| Gupta, S | 1 |
| Singal, A | 1 |
| Soni, R | 1 |
| Brooks, BR | 1 |
| Heiman-Patterson, T | 1 |
| Wiedau-Pazos, M | 1 |
| Liu, S | 2 |
| Zhang, J | 2 |
| Apple, S | 1 |
| Park, JM | 1 |
| Park, D | 1 |
| Kim, HJ | 1 |
| Park, JS | 1 |
| Ohta, Y | 1 |
| Yamashita, T | 1 |
| Nomura, E | 1 |
| Hishikawa, N | 1 |
| Ikegami, K | 1 |
| Osakada, Y | 1 |
| Matsumoto, N | 1 |
| Kawahara, Y | 1 |
| Yunoki, T | 1 |
| Takahashi, Y | 1 |
| Takamiya, M | 1 |
| Tadokoro, K | 1 |
| Sasaki, R | 1 |
| Nakano, Y | 1 |
| Tsunoda, K | 1 |
| Sato, K | 1 |
| Omote, Y | 1 |
| Takemoto, M | 1 |
| Abe, K | 2 |
| Sawada, H | 1 |
| Hardiman, O | 2 |
| van den Berg, LH | 2 |
| Takei, K | 4 |
| Watanabe, K | 1 |
| Yuki, S | 2 |
| Akimoto, M | 3 |
| Sakata, T | 1 |
| Palumbo, J | 4 |
| Maragakis, NJ | 1 |
| Takahashi, F | 3 |
| Tsuda, K | 3 |
| Kalin, A | 1 |
| Medina-Paraiso, E | 1 |
| Ishizaki, K | 1 |
| Kim, A | 1 |
| Zhang, Y | 1 |
| Saita, T | 1 |
| Wasaki, M | 1 |
| Nakamura, K | 1 |
| Mora, JS | 1 |
| Tao, QQ | 1 |
| Wu, ZY | 1 |
| Al-Chalabi, A | 1 |
| Andersen, PM | 1 |
| Chandran, S | 1 |
| Chio, A | 1 |
| Corcia, P | 1 |
| Couratier, P | 1 |
| Danielsson, O | 1 |
| de Carvalho, M | 1 |
| Desnuelle, C | 1 |
| Grehl, T | 1 |
| Grosskreutz, J | 1 |
| Holmøy, T | 1 |
| Ingre, C | 1 |
| Karlsborg, M | 1 |
| Kleveland, G | 1 |
| Koch, JC | 1 |
| Koritnik, B | 1 |
| KuzmaKozakiewicz, M | 1 |
| Laaksovirta, H | 1 |
| Ludolph, A | 1 |
| McDermott, C | 1 |
| Meyer, T | 1 |
| Mitre Ropero, B | 1 |
| Mora Pardina, J | 1 |
| Nygren, I | 1 |
| Petri, S | 1 |
| Povedano Panades, M | 1 |
| Salachas, F | 1 |
| Shaw, P | 1 |
| Silani, V | 1 |
| Staaf, G | 1 |
| Svenstrup, K | 1 |
| Talbot, K | 1 |
| Tysnes, OB | 1 |
| Van Damme, P | 1 |
| van der Kooi, A | 1 |
| Weber, M | 1 |
| Weydt, P | 1 |
| Wolf, J | 1 |
| Scott, A | 1 |
| Rothstein, JD | 1 |
| Yeo, CJJ | 1 |
| Simmons, Z | 1 |
| Bhandari, R | 1 |
| Kuhad, A | 2 |
| Genge, A | 1 |
| Brooks, B | 1 |
| Itoyama, Y | 2 |
| Sobue, G | 1 |
| Tsuji, S | 1 |
| Aoki, M | 2 |
| Doyu, M | 1 |
| Hamada, C | 1 |
| Kondo, K | 1 |
| Yoneoka, T | 1 |
| Yoshino, H | 3 |
| Nagase, M | 1 |
| Yamamoto, Y | 1 |
| Miyazaki, Y | 1 |
| Ikeda, K | 1 |
| Iwasaki, Y | 1 |
| Noto, Y | 1 |
| Shibuya, K | 1 |
| Vucic, S | 1 |
| Kiernan, MC | 1 |
| Martinez, A | 1 |
| Palomo Ruiz, MD | 1 |
| Perez, DI | 1 |
| Gil, C | 1 |
| Ito, H | 2 |
| Wate, R | 1 |
| Ohnishi, S | 1 |
| Kaneko, S | 1 |
| Nakano, S | 1 |
| Kusaka, H | 1 |
| Takahashi, R | 1 |
| Warita, H | 1 |
| Mizuno, H | 1 |
| Suzuki, N | 1 |
| Zona, C | 1 |
| Pieri, M | 1 |
| Carunchio, I | 1 |
| Kimura, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Interplay Between Gut Microbiota and Adaptive Immunity in Amyotrophic Lateral Sclerosis: a Clinical Trial[NCT03766321] | 42 participants (Actual) | Interventional | 2020-07-01 | Active, not recruiting | |||
| Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS) in a Representative Iranian Population[NCT03272802] | Phase 2/Phase 3 | 20 participants (Anticipated) | Interventional | 2017-03-16 | Active, not recruiting | ||
| Efficacy and Safety Study of MCI-186 for Treatment of the Patients With Amyotrophic Lateral Sclerosis (ALS) 2[NCT01492686] | Phase 3 | 137 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Efficacy and Safety of Nerve Growth Factor or Edaravone on Alcohol-induced Brain Injury[NCT03968042] | Phase 2 | 150 participants (Anticipated) | Interventional | 2019-06-30 | Recruiting | ||
| An Expanded Controlled Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-Blind, Parallel-Group, Placebo-Controlled Manner (Phase 3)[NCT00424463] | Phase 3 | 181 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| An Exploratory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (Severity Classification III) in Double-Blind, Parallel-Group, Placebo-Controlled Manner[NCT00415519] | Phase 3 | 25 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis: A Phase IIa Study[NCT03580616] | Phase 2 | 43 participants (Actual) | Interventional | 2018-10-24 | Terminated (stopped due to Study was terminated by the IRB due to continued noncompliance.) | ||
| A Confirmatory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-blind, Parallel-group, Placebo-controlled Manner.[NCT00330681] | Phase 3 | 206 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01492686)
Timeframe: baseline and 24 weeks
| Intervention | percentage of FVC (Least Squares Mean) |
|---|---|
| MCI-186 | -15.61 |
| Placebo of MCI-186 | -20.4 |
The ALSAQ40 score is a measure of QoL for patients with ALS. The ALSAQ40 evaluates domains that include physical mobility, Activities of daily living (ADL) and independence, eating and drinking, communication, and emotional reactions. 200=worst; 40=best (NCT01492686)
Timeframe: baseline and 24 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| MCI-186 | 17.25 |
| Placebo of MCI-186 | 26.04 |
The Modified Norris Scale is a measure of movement disorder for patients with ALS. 0=worst; 102=best (NCT01492686)
Timeframe: baseline and 24 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| MCI-186 | -15.91 |
| Placebo of MCI-186 | -20.8 |
0=worst; 48=best (NCT01492686)
Timeframe: baseline and 24 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| MCI-186 | -5.01 |
| Placebo of MCI-186 | -7.5 |
(NCT01492686)
Timeframe: 24 weeks
| Intervention | percentage of Participants (Number) |
|---|---|
| MCI-186 | 2.9 |
| Placebo of MCI-186 | 7.4 |
(NCT01492686)
Timeframe: 24 weeks
| Intervention | percentage of Participants (Number) |
|---|---|
| MCI-186 | 84.1 |
| Placebo of MCI-186 | 83.8 |
(NCT01492686)
Timeframe: 24 weeks
| Intervention | percentage of Participants (Number) | |||
|---|---|---|---|---|
| Blood bilirubin increased | Blood creatine phosphokinase increased | Liver function test abnormal | White blood cell count decreased | |
| MCI-186 | 0 | 0 | 1.4 | 1.4 |
| Placebo of MCI-186 | 1.5 | 1.5 | 1.5 | 0 |
"Any of death, disability of independent ambulation, loss of upper limbs function, tracheotomy, use of respirator, use of tube feeding and loss of useful speech was defined as an event." (NCT01492686)
Timeframe: 24 weeks
| Intervention | Count of Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Death | Disability of independent ambulation | Loss of upper limbs function | Tracheotomy | Use of respirator | Use of tube feeding | Loss of useful speech | |
| MCI-186 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Placebo of MCI-186 | 0 | 2 | 0 | 0 | 0 | 1 | 3 |
(NCT01492686)
Timeframe: baseline and 24 weeks
| Intervention | percentage of Participants (Number) | |||
|---|---|---|---|---|
| Numbness (at baseline) | Numbness (at 24 week) | Staggering (at baseline) | Staggering (at 24 week) | |
| MCI-186 | 2.9 | 7.2 | 1.4 | 2.9 |
| Placebo of MCI-186 | 7.4 | 9.4 | 8.8 | 3.1 |
To investigate the sustainability of effects of edaravone, the analysis focusing on the comparison between the placebo and edaravone groups of patients who had received 6 cycles of edaravone treatment, i.e., the comparison of data from Cycles 7 to 12 between the edaravone-edaravone group and the edaravone-placebo group, was performed. (NCT00424463)
Timeframe: baseline (seventh cycle) and at 24 week (twelfth cycle)
| Intervention | percentage of FVC (Mean) |
|---|---|
| MCI-186 - Placebo of MCI-186 | -10.6 |
| MCI-186 - MCI-186 | -12.91 |
| Placebo of MCI-186 - MCI-186 | -10.54 |
0=worst; 48=best To investigate the sustainability of effects of edaravone, the analysis focusing on the comparison between the placebo and edaravone groups of patients who had received 6 cycles of edaravone treatment, i.e., the comparison of data from Cycles 7 to 12 between the edaravone-edaravone group and the edaravone-placebo group, was performed. (NCT00424463)
Timeframe: baseline (seventh cycle) and at 24 week (twelfth cycle)
| Intervention | units on a scale (Mean) |
|---|---|
| MCI-186 - Placebo of MCI-186 | -5.5 |
| MCI-186 - MCI-186 | -4.2 |
| Placebo of MCI-186 - MCI-186 | -5.4 |
(NCT00424463)
Timeframe: 36 weeks (from seventh cycle to fifteenth cycle)
| Intervention | percentage of participant (Number) |
|---|---|
| MCI-186 - Placebo of MCI-186 | 4.4 |
| MCI-186 - MCI-186 | 10.4 |
| Placebo of MCI-186 - MCI-186 | 10.2 |
(NCT00424463)
Timeframe: 36 weeks (from seventh cycle to fifteenth cycle)
| Intervention | percentage of participant (Number) |
|---|---|
| MCI-186 - Placebo of MCI-186 | 97.8 |
| MCI-186 - MCI-186 | 91.7 |
| Placebo of MCI-186 - MCI-186 | 92 |
"Any of death, disability of independent ambulation, loss of upper arm function, tracheotomy, use of respirator, and use of tube feeding was defined as an event." (NCT00424463)
Timeframe: 24 weeks (from seventh cycle to twelfth cycle)
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| death | disability of independent ambulation | loss of upper arm function | tracheotomy | use of respirator | use of tube feeding | |
| MCI-186 - MCI-186 | 1 | 11 | 5 | 0 | 1 | 1 |
| MCI-186 - Placebo of MCI-186 | 1 | 8 | 3 | 0 | 0 | 1 |
| Placebo of MCI-186 - MCI-186 | 1 | 20 | 7 | 2 | 2 | 8 |
(NCT00424463)
Timeframe: 36 weeks (from seventh cycle to fifteenth cycle)
| Intervention | percentage of participant (Number) | ||
|---|---|---|---|
| Numbness | Staggering | Vibratory sensation | |
| MCI-186 - MCI-186 | 0 | 2.1 | 0 |
| MCI-186 - Placebo of MCI-186 | 0 | 0 | 0 |
| Placebo of MCI-186 - MCI-186 | 0 | 2.3 | 0 |
(NCT00424463)
Timeframe: 36 weeks (from seventh cycle to fifteenth cycle)
| Intervention | percentage of participant (Number) | ||
|---|---|---|---|
| White blood cell count | Alanine aminotransferase | Urinary glucose | |
| MCI-186 - MCI-186 | 4.2 | 6.3 | 6.3 |
| MCI-186 - Placebo of MCI-186 | 11.1 | 0 | 0 |
| Placebo of MCI-186 - MCI-186 | 10.2 | 4.5 | 3.4 |
No primary endpoint was used, because various exploratory analyses were performed. (NCT00415519)
Timeframe: baseline and 24 weeks
| Intervention | percentage of FVC (Least Squares Mean) |
|---|---|
| MCI-186 | -18.75 |
| Placebo of MCI-186 | -15.69 |
"No primary endpoint was used, because various exploratory analyses were performed.~0=worst; 48=best" (NCT00415519)
Timeframe: baseline and 24 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| MCI-186 | -6.52 |
| Placebo of MCI-186 | -6 |
No primary endpoint was used, because various exploratory analyses were performed. (NCT00415519)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MCI-186 | 23.1 |
| Placebo of MCI-186 | 8.3 |
No primary endpoint was used, because various exploratory analyses were performed. (NCT00415519)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MCI-186 | 92.3 |
| Placebo of MCI-186 | 100 |
"No primary endpoint was used, because various exploratory analyses were performed.~Any of death, disability of independent ambulation, loss of upper arm function, tracheotomy, use of respirator, and use of tube feeding was defined as an event." (NCT00415519)
Timeframe: 24 weeks
| Intervention | events (Number) | |||||
|---|---|---|---|---|---|---|
| death | disability of independent ambulation | loss of upper arm function | tracheotomy | use of respirator | use of tube feeding | |
| MCI-186 | 1 | 4 | 1 | 0 | 0 | 1 |
| Placebo of MCI-186 | 0 | 2 | 2 | 0 | 0 | 0 |
No primary endpoint was used, because various exploratory analyses were performed. (NCT00415519)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Numbness | Staggering | Vibratory sensation | |
| MCI-186 | 0 | 10 | 0 |
| Placebo of MCI-186 | 0 | 0 | 0 |
No primary endpoint was used, because various exploratory analyses were performed. (NCT00415519)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) | |
|---|---|---|
| White blood cell count (WBC) | Other laboratory tests except for WBC | |
| MCI-186 | 23.1 | 0 |
| Placebo of MCI-186 | 8.3 | 0 |
(NCT00330681)
Timeframe: baseline and 24 weeks
| Intervention | percentage of FVC (Least Squares Mean) |
|---|---|
| MCI-186 | -14.57 |
| Placebo of MCI-186 | -17.49 |
The ALSAQ40 score is a measure of QoL for patients with ALS. The ALSAQ40 evaluates domains that include physical mobility, ADL and independence, eating and drinking, communication, and emotional reactions. Worst=200, Best=40 (NCT00330681)
Timeframe: baseline and 24 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| MCI-186 | 19.6 |
| Placebo of MCI-186 | 19.13 |
The Modified Norris Scale is a measure of movement disorder for patients with ALS. Worst=0, Best=102 (NCT00330681)
Timeframe: baseline and 24 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| MCI-186 | -14.12 |
| Placebo of MCI-186 | -16.15 |
ALSFRS-R Score: 0=worst; 48=best (NCT00330681)
Timeframe: baseline and 24 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| MCI-186 | -5.7 |
| Placebo of MCI-186 | -6.35 |
(NCT00330681)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MCI-186 | 13.7 |
| Placebo of MCI-186 | 19.2 |
(NCT00330681)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MCI-186 | 89.2 |
| Placebo of MCI-186 | 88.5 |
"Any of death, disability of independent ambulation, loss of upper arm function, tracheotomy, use of respirator, and use of tube feeding was defined as an event." (NCT00330681)
Timeframe: 24 weeks
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| death | disability of independent ambulation | loss of upper arm function | tracheotomy | use of respirator | use of tube feeding | |
| MCI-186 | 2 | 28 | 2 | 0 | 1 | 5 |
| Placebo of MCI-186 | 2 | 23 | 4 | 2 | 3 | 3 |
(NCT00330681)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Numbness | Staggering | Vibratory sensation | |
| MCI-186 | 1 | 2 | 0 |
| Placebo of MCI-186 | 1 | 3.8 | 1 |
(NCT00330681)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) | |
|---|---|---|
| White blood cell count | urinary glucose | |
| MCI-186 | 2 | 6.9 |
| Placebo of MCI-186 | 5.8 | 2.9 |
7 reviews available for antipyrine and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antipyrine; Disease Models, Animal; Edaravone; Free Radical | 2017 |
Edaravone and its clinical development for amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Clinical Trials as Topic; Edaravone; Free Radical Scaveng | 2017 |
What can we learn from the edaravone development program for ALS?
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Clinical Trials as Topic; Edaravone; Free Radical Scaveng | 2017 |
July 2017 ENCALS statement on edaravone.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Decision Making; Edaravone; Free Radical Scavengers; Huma | 2017 |
Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Edaravone; Free Radical Scavengers; Humans; Neuroprotecti | 2018 |
Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Edaravone; Humans; Motor Neurons; Neuroprotective Agents; | 2016 |
Drugs in clinical development for the treatment of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antipyrine; Biological Therapy; Biomarkers; Cell- and Tissue | 2017 |
13 trials available for antipyrine and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686].
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Double-Blind Method; Edaravone; Free Radical Scavengers; | 2022 |
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Antipyrine; Double-Blind Method; Edaravone; Female; Free | 2017 |
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Antipyrine; Double-Blind Method; Edaravone; Female; Free | 2017 |
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Antipyrine; Double-Blind Method; Edaravone; Female; Free | 2017 |
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Antipyrine; Double-Blind Method; Edaravone; Female; Free | 2017 |
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Antipyrine; Double-Blind Method; Edaravone; Female; Free | 2017 |
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Antipyrine; Double-Blind Method; Edaravone; Female; Free | 2017 |
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Antipyrine; Double-Blind Method; Edaravone; Female; Free | 2017 |
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Antipyrine; Double-Blind Method; Edaravone; Female; Free | 2017 |
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Antipyrine; Double-Blind Method; Edaravone; Female; Free | 2017 |
Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis.
Topics: Aged; Amyotrophic Lateral Sclerosis; Antipyrine; Double-Blind Method; Edaravone; Female; Free Radica | 2017 |
Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Antipyrine; Double-Blind Method; Edaravone; Female; Free | 2017 |
Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
Topics: Activities of Daily Living; Adult; Aged; Amyotrophic Lateral Sclerosis; Antipyrine; Double-Blind Met | 2017 |
Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Double-Blind Method; Edaravone; Female; Free Radical Scav | 2017 |
A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
Topics: Aged; Amyotrophic Lateral Sclerosis; Antipyrine; Double-Blind Method; Edaravone; Female; Free Radica | 2017 |
Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Antipyrine; Double-Blind Method; Edaravone; Female; Free | 2017 |
A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Antipyrine; Double-Blind Method; Edaravone; Female; Free | 2017 |
Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Antipyrine; Double-Blind Method; Edaravone; Female; Free | 2017 |
Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Analysis of Variance; Antipyrine; Double-Blind Method; E | 2014 |
Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Analysis of Variance; Antipyrine; Double-Blind Method; E | 2014 |
Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Analysis of Variance; Antipyrine; Double-Blind Method; E | 2014 |
Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Analysis of Variance; Antipyrine; Double-Blind Method; E | 2014 |
Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Analysis of Variance; Antipyrine; Double-Blind Method; E | 2014 |
Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Analysis of Variance; Antipyrine; Double-Blind Method; E | 2014 |
Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Analysis of Variance; Antipyrine; Double-Blind Method; E | 2014 |
Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Analysis of Variance; Antipyrine; Double-Blind Method; E | 2014 |
Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Analysis of Variance; Antipyrine; Double-Blind Method; E | 2014 |
Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration.
Topics: Aged; Amyotrophic Lateral Sclerosis; Antipyrine; Biomarkers; Edaravone; Fatty Acids, Nonesterified; | 2016 |
Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study).
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Dose-Response Relationship, Drug; Edaravone; Female; Free | 2006 |
18 other studies available for antipyrine and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Efficacy and Safety of Edaravone in Amyotrophic Lateral Sclerosis Patients in Indian Population.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antipyrine; Double-Blind Method; Edaravone; Humans; Neurodeg | 2022 |
Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Double-Blind Method; Edaravone; Humans; Neurodegenerative | 2022 |
In brief: Edaravone oral suspension (Radicava ORS) for ALS.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Edaravone; Electrolytes; Free Radical Scavengers; Humans; | 2022 |
Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Edaravone; Free Radical Scavengers; Humans; Oxidation-Red | 2020 |
Edaravone: a new treatment for ALS on the horizon?
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Edaravone; Free Radical Scavengers; Humans | 2017 |
Edaravone for treatment of early-stage ALS - Authors' reply.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Edaravone; Free Radical Scavengers; Humans | 2017 |
Edaravone for treatment of early-stage ALS.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Edaravone; Free Radical Scavengers; Humans | 2017 |
Amyotrophic Lateral Sclerosis: Precise Diagnosis and Individualized Treatment.
Topics: Adaptor Proteins, Signal Transducing; Amyotrophic Lateral Sclerosis; Antipyrine; Autophagy-Related P | 2017 |
Drug therapy: On the treatment trail for ALS.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Benzamides; C9orf72 Protein; Clinical Trials as Topic; Di | 2017 |
Edaravone: A new drug approved for ALS.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Drug Approval; Edaravone; Excitatory Amino Acid Antagonis | 2017 |
Edaravone (Radicava) for ALS.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Edaravone; Free Radical Scavengers; Humans; Oxidative Str | 2017 |
Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Clinical Trials as Topic; Cost-Benefit Analysis; Edaravon | 2018 |
Edaravone administration in pivotal clinical Study 19.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Edaravone; Free Radical Scavengers; Humans | 2019 |
Edaravone, a Free Radical Scavenger, Delayed Symptomatic and Pathological Progression of Motor Neuron Disease in the Wobbler Mouse.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antipyrine; Astrocytes; Disease Models, Animal; Disease Prog | 2015 |
Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antipyrine; Edaravone; Female; Humans; Male; Mice; Mice, Tra | 2008 |
Edaravone in ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antipyrine; Clinical Trials as Topic; Disease Models, Animal | 2009 |
Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antipyrine; Disease Models, Animal; Edaravone; Feasibility S | 2011 |
Voltage-dependent sodium channels in spinal cord motor neurons display rapid recovery from fast inactivation in a mouse model of amyotrophic lateral sclerosis.
Topics: Algorithms; Amino Acid Substitution; Amyotrophic Lateral Sclerosis; Animals; Antipyrine; Cells, Cult | 2006 |